Table 2.
Demographic and clinical characteristics of HER2 positive Breast Cancer Patients
| Demographic and clinical characteristics | Total |
|---|---|
| N = 348 | |
| Age at study inclusion (years), n = 348 | |
| Mean ± SD | 54.07 ± 11.55 |
| Age at breast cancer diagnosis (years), n = 344 | |
| Mean ± SD | 48.14 ± 11.67 |
| Sex, n = 348 | |
| Male | 3 (0.9%) |
| Female | 345 (99.1%) |
| Nationality, n = 348 | |
| Saudi Arabian | 322 (92.5%) |
| Other | 26 (7.5%) |
| Body Mass Index (kg/m2), n = 262 | |
| Mean ± SD | 30.56 ± 6.35 |
| Breast cancer stage based on TNM classification at diagnosis, n = 260 | |
| Stage I | 19 (7.3%) |
| Stage II | 103 (39.6%) |
| Stage III A | 57 (21.9%) |
| Stage III B | 47 (18.1%) |
| Stage IV | 34 (13.1%) |
| Metastatic sites, n = 30 | |
| Bone | 15 (50.0%) |
| Lung | 13 (43.3%) |
| Liver | 13 (43.3%) |
| Lymph node | 4 (13.3%) |
| Brain | 3 (10.0%) |
| Ovaries | 1 (3.3%) |
| Peritoneum | 1 (3.3%) |
| Primary cancer site, n = 348 | |
| Right | 175 (50.3%) |
| Left | 164 (47.1%) |
| Bilateral | 8 (2.3%) |
| Unknown | 1 (0.3%) |
| Performance status, n = 187 | |
| Performance status = 0 | 20 (10.7%) |
| Performance status = 1 | 122 (65.2%) |
| Performance status = 2 | 31 (16.6%) |
| Performance status = 3 | 9 (4.8%) |
| Performance status = 4 | 5 (2.7%) |
| Performance status = 5 | 0 (0.0%) |
| Site of biopsy, n = 348 | |
| Primary tumor site | 328 (94.3%) |
| Metastatic tumor site | 15 (4.3%) |
| Unknown, not recorded | 5 (1.4%) |
| HER2 test method, n = 348 | |
| FISH | 53 (15.3%) |
| IHC | 294 (84.7%) |
| Curative intent surgery performed, n = 348 | |
| Yes | 293 (84.2%) |
| No | 55 (15.8%) |
| If Yes, tumor size (cm), n = 264 | |
| Mean ± SD | 3.5 ± 2.5 |
| Breast cancer pathology, n = 283 | |
| Infiltrating ductal carcinoma | 263 (92.9%) |
| Infiltrating lobular carcinoma | 0 (0.0%) |
| Medullary carcinoma | 0 (0.0%) |
| Inflammatory breast cancer | 2 (0.7%) |
| Tubular carcinoma | 1 (0.4%) |
| Mucinous carcinoma | 2 (0.7%) |
| Ductal carcinoma in situ | 13 (4.6%) |
| Invasive ductal carcinoma | 2 (0.7%) |
| Hormone-receptor status, n = 340 | |
| ER-/PR- | 144 (42.4%) |
| ER + and/or PR + | 196 (57.6%) |
| Tumor margins, n = 265 | |
| Negative | 245 (92.5%) |
| Positive | 20 (7.5%) |
| More than one tumor in the breast, n = 346 | |
| Yes | 58 (16.8%) |
| No | 288 (83.2%) |
| If Yes, tumor origin, n = 53 | |
| Multifocal breast cancer | 33 (62.3%) |
| Multicentric breast cancer | 20 (37.7%) |
| Lymphovascular invasion, n = 289 | |
| Yes | 121 (41.9%) |
| No | 168 (58.3%) |
| Axillary lymph nodes examined (sentinel, sampling, dissection), n = 313 | |
| Yes | 256 (81.8%) |
| No | 57 (18.2%) |
| Number of lymph nodes examined, n = 254 | |
| Mean ± SD | 14.5 ± 11.2 |
| Number of lymph nodes involved, n = 253 | |
| Mean ± SD | 3.7 ± 7.6 |
| Clinical response at last patient evaluation, n = 217 | |
| Stable disease | 61 (28.1%) |
| Progressive disease | 72 (33.2%) |
| Partial response | 4 (1.8%) |
| Complete response | 80 (36.9%) |
SD standard deviation, FISH fluorescent in situ hybridization, IHC ImmunoHistoChemistry, ER estrogen receptor, PR progesterone receptor